Release Date - September 17, 2007

Velcera to Present at Maxim Group Growth Conference

YARDLEY, PA — Velcera, Inc., a specialty pharmaceutical company focused on pet health, announced today that the company will be presenting at the Maxim Group Growth Conference September 20, 2007 at the Grand Hyatt Hotel in New York City. The company's chief executive officer, Dennis Steadman, is scheduled to present a corporate overview and update on clinical programs evaluating its PROMIST™ delivery system on Thursday, September 20 at 8:00 a.m. (EDT) in Track Four.

To access a live audio webcast of Mr. Steadman's presentation, please log onto Velcera's website at http://www.corporate-ir.net/ireye/confLobby.zhtml? ticker=W215153&item_id approximately 15 minutes prior to the presentation in order to register and download any necessary software. Shortly after the presentation, the webcast will be available on Velcera's we site at www.velcera.com and archived for 90 days.

The Maxim Group Growth Conference will feature interactive presentations from over 70 companies, as well as one-on-one meetings with executives from the Healthcare, Technology, and Special Situations Sectors. For more information on this event please visit http://www.maximgrp.com/growthconf/ .

About Velcera, Inc.

Velcera is a specialty pharmaceutical company focused on leveraging its patented PROMIST™ delivery system to develop veterinary medicines with superior convenience, compliance, and pharmacokinetic advantages that benefit pets and their owners. The PROMIST delivery system provides a metered dose liquid mist to the oral mucosa for systemic absorption. The convenience of PROMIST has the potential to increase compliance and improve pet health as owners avoid the challenge involved in getting their pets to swallow pills. Other advantages of PROMIST include improved bioavailability, faster absorption and avoidance of the GI track.

As a patented technology, PROMIST attracts strategic partners by extending the patent life of medication based on the delivery system. Current collaborations include a global licensing agreement with Novartis Animal Health covering Velcera's first product, a novel canine product utilizing Velcera's patented PROMIST technology, as well as formulation and manufacturing agreements with The Chao Center at the University of Purdue and Argenta Manufacturing Ltd. To date, PROMIST has shown significantly improved bioavailabilty, drug uptake, and ease of administration when evaluated in dogs, cats and horses.

For more information, please contact:

# # #

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks that may affect forward-looking information contained in this press release include, without limitation, the risk that the results of clinical trials may not support our claims and our lack of experience in developing and commercializing pet pharmaceutical products. Additional risks are described in our Current Report on Form SB-2/A filed with the Securities and Exchange Commission on June 21, 2007. We assume no obligation to update these statements, except as required by law.